| Literature DB >> 26040932 |
Masatsune Shibutani1, Kiyoshi Maeda2, Hisashi Nagahara3, Hiroshi Ohtani4, Yasuhito Iseki5, Tetsuro Ikeya6, Kenji Sugano7, Kosei Hirakawa8.
Abstract
BACKGROUND: Recently, a preoperative systemic inflammatory response has been reported to be a prognostic factor in patients with colorectal cancer (CRC). However, the prognostic significance of a systemic inflammatory response in the early stage after surgery in patients with CRC is unknown. The aim of this retrospective study was to evaluate the prognostic significance of a postoperative systemic inflammatory response in patients with CRC.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26040932 PMCID: PMC4460765 DOI: 10.1186/s12957-015-0609-3
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
The patient characteristics
| Gender | |
| Male | 139 |
| Female | 115 |
| Age (years) | |
| Median (range) | 66 (26–86) |
| Location of primary tumor | |
| Colon | 131 |
| Rectum | 123 |
| Tumor depth | |
| T1-3 | 176 |
| T4 | 77 |
| Histological type | |
| Well, moderately | 234 |
| Poorly, mucinous | 19 |
| Lymphatic involvement | |
| Negative | 47 |
| Positive | 184 |
| Venous involvement | |
| Negative | 170 |
| Positive | 68 |
| Number of lymph node metastases | |
| 0 | 85 |
| 1–3 | 116 |
| ≥4 | 53 |
| Stage | |
| II | 85 |
| III | 169 |
| Regimen of chemotherapy | |
| Oral 5-FU monotherapy | 178 |
| CapeOX | 19 |
| FOLFOX | 11 |
| None | 46 |
| Median value of indicators of the preoperative systemic inflammatory response (range) | |
| NLR | 2.26 (0.87–10.24) |
| CRP (mg/dl) | 0.11 (0.01–13.99) |
| Preoperative serum albumin level (g/dl) | |
| Median (range) | 4.1 (2.6–4.8) |
| Median value of indicators of the postoperative systemic inflammatory response (range) | |
| NLR | 1.82 (0.18–10.11) |
| CRP (mg/dl) | 0.09 (0.01–17.09) |
| Postoperative serum albumin level (g/dl) | |
| Median (range) | 4.0 (3.0–4.7) |
| The number of days from operation until the first visit after leaving the hospital | |
| Median (interquartile range) | 29 (23–36) |
5-FU 5-fluorouracil, CapeOX capecitabine plus oxaliplatin, FOLFOX 5-fluorouracil/leucovorin plus oxaliplatin, NLR neutrophil-to-lymphocyte ratio, CRP C-reactive protein
Fig. 1a Receiver-operating characteristic-curve analysis of the preoperative NLR. Area under the curve = 0.618, 95 % confidence interval = 0.502–0.735, p = 0.053. b Receiver-operating characteristic-curve analysis of the postoperative NLR. Area under the curve = 0.680, 95 % confidence interval = 0.573–0.787, p = 0.002
The distribution of patients based on the indicators of the postoperative systemic inflammatory response
| Preoperation | Postoperation | |
|---|---|---|
| NLR | ||
| Low | 99 (61.5 %) | 183 (84.3 %) |
| High | 62 (38.5 %) | 34 (15.7 %) |
| GPS | ||
| 0 | 174 (77.7 %) | 159 (77.6 %) |
| 1 | 44 (19.6 %) | 39 (19.0 %) |
| 2 | 6 (2.7 %) | 7 (3.4 %) |
NLR neutrophil-to-lymphocyte ratio, GPS Glasgow prognostic score
Fig. 2a The overall survival according to the preoperative NLR. The overall survival rates were significantly worse in the high preoperative NLR group (p = 0.0388). b The overall survival according to the preoperative GPS. The overall survival rates were significantly worse in the high preoperative GPS group (p = 0.0028)
Fig. 3a The overall survival according to the postoperative NLR. The overall survival rates were significantly worse in the high postoperative NLR group (p = 0.0006). b The overall survival according to the postoperative GPS. There was no relationship between the postoperative GPS and mortality
The correlation between the postoperative systemic inflammatory response and the clinicopathological factors
| Postoperative NLR | Postoperative GPS | |||||
|---|---|---|---|---|---|---|
| <3 | ≥3 |
| 0 | 1,2 |
| |
| Age (years) | ||||||
| <70 | 120 | 19 | 102 | 28 | ||
| ≥70 | 63 | 15 | 0.331 | 57 | 18 | 0.729 |
| Gender | ||||||
| Male | 97 | 24 | 84 | 27 | ||
| Female | 86 | 10 | 0.063 | 75 | 19 | 0.506 |
| Location | ||||||
| Colon | 93 | 19 | 86 | 22 | ||
| Rectum | 90 | 15 | 0.709 | 73 | 24 | 0.504 |
| Tumor depth | ||||||
| T1-3 | 133 | 22 | 112 | 33 | ||
| T4 | 49 | 12 | 0.406 | 47 | 13 | 1.000 |
| Histological type | ||||||
| Well, moderately | 170 | 31 | 147 | 43 | ||
| Poorly, mucinous | 12 | 3 | 0.711 | 12 | 2 | 0.739 |
| Lymphatic involvement | ||||||
| Negative | 39 | 5 | 35 | 3 | ||
| Positive | 124 | 27 | 0.363 | 112 | 37 | 0.026 |
| Venous involvement | ||||||
| Negative | 123 | 24 | 109 | 35 | ||
| Positive | 46 | 9 | 1.000 | 41 | 8 | 0.321 |
| Number of lymph node metastases | ||||||
| 0 | 75 | 8 | 60 | 7 | ||
| 1–3 | 71 | 19 | 64 | 30 | ||
| ≥4 | 37 | 7 | 0.116 | 35 | 9 | 0.005 |
| Preoperative CEA (>5 ng/ml) | ||||||
| Negative | 129 | 25 | 116 | 29 | ||
| Positive | 38 | 6 | 0.816 | 35 | 8 | 1.000 |
| Preoperative CA19-9 (>37 U/ml) | ||||||
| Negative | 158 | 28 | 145 | 33 | ||
| Positive | 5 | 2 | 0.298 | 3 | 4 | 0.031 |
| Adjuvant chemotherapy | ||||||
| No | 40 | 4 | 35 | 8 | ||
| Yes | 143 | 30 | 0.246 | 124 | 28 | 0.545 |
| Length of operation (min) | ||||||
| Median (range) | 199 (79–430) | 230 (84–687) | 0.010 | 203 (79–687) | 206 (110–372) | 0.681 |
| Blood loss (ml) | ||||||
| Median (range) | 80 (5–1785) | 220 (10–2700) | <0.001 | 80 (5–2700) | 90 (10–1880) | 0.495 |
| Postoperative infectious complication | ||||||
| No | 137 | 25 | 121 | 34 | ||
| Yes | 46 | 9 | 0.833 | 38 | 12 | 0.846 |
| Preoperative NLR | ||||||
| <2.5 | 70 | 12 | ||||
| ≥2.5 | 45 | 8 | 1.000 | |||
| Preoperative GPS | ||||||
| 0 | 131 | 21 | ||||
| 1,2 | 24 | 20 | <0.001 | |||
NLR neutrophil-to-lymphocyte ratio, GPS Glasgow prognostic score, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
The correlation between the postoperative systemic inflammatory response and the sub-classification of the postoperative infectious complications
| Postoperative NLR | Postoperative GPS | |||||
|---|---|---|---|---|---|---|
| <3 | ≥3 |
| 0 | 1,2 |
| |
| Criteria according to Clavien-Dindo classification | ||||||
| Without complication, grade I | 131 | 21 | 113 | 33 | ||
| Grade ≥II | 50 | 13 | 0.223 | 45 | 13 | 1.000 |
| Wound infection | ||||||
| No | 168 | 33 | 150 | 41 | ||
| Yes | 15 | 1 | 0.477 | 9 | 5 | 0.315 |
| Anastomotic leakage | ||||||
| No | 171 | 31 | 149 | 42 | ||
| Yes | 12 | 3 | 0.710 | 10 | 4 | 0.521 |
| Abdominal abscess | ||||||
| No | 176 | 33 | 154 | 45 | ||
| Yes | 7 | 1 | 1.000 | 5 | 1 | 1.000 |
| Enterocolitis | ||||||
| No | 176 | 33 | 153 | 46 | ||
| Yes | 7 | 1 | 1.000 | 6 | 0 | 0.341 |
| Pneumonia | ||||||
| No | 183 | 33 | 158 | 46 | ||
| Yes | 0 | 1 | 0.157 | 1 | 0 | 1.000 |
| Urinary tract infection | ||||||
| No | 181 | 33 | 157 | 45 | ||
| Yes | 2 | 1 | 0.402 | 2 | 1 | 0.535 |
| Duodenal perforation | ||||||
| No | 183 | 33 | 158 | 46 | ||
| Yes | 0 | 1 | 0.157 | 1 | 0 | 1.000 |
NLR neutrophil-to-lymphocyte ratio, GPS Glasgow prognostic score
The correlations between the overall survival and various clinicopathological factors
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95 % CI |
| Hazard ratio | 95 % CI |
| |
| Age (>70 years) | 2.113 | 1.142–3.911 | 0.017 | 0.912 | 0.204–4.083 | 0.904 |
| Gender (Male) | 0.684 | 0.361–1.295 | 0.243 | |||
| Location of primary tumor (Colon) | 0.749 | 0.404-1.389 | 0.360 | |||
| Tumor depth (T4) | 1.863 | 1.007–3.448 | 0.048 | 4.592 | 0.896–23.544 | 0.068 |
| Histological type (Poorly, mucinous) | 3.449 | 1.582–7.518 | 0.002 | 0 | 0 | 0.988 |
| Lymphatic involvement (Positive) | 2.744 | 0.839–8.979 | 0.095 | |||
| Venous involvement (Positive) | 2.102 | 1.080–4.093 | 0.029 | 0.350 | 0.068–1.800 | 0.209 |
| Number of lymph node metastases | 2.924 | 1.816–4.707 | <0.001 | 14.677 | 2.571–83.779 | 0.003 |
| Preoperative CEA (>5 ng/ml) | 1.939 | 0.875–4.299 | 0.103 | |||
| Preoperative CA19-9 (>37 U/ml) | 1.298 | 0.176–9.586 | 0.798 | |||
| Adjuvant chemotherapy (Yes) | 0.332 | 0.080–1.384 | 0.130 | |||
| Chemotherapy regimen (with oxaliplatin) | 0.726 | 0.216–2.433 | 0.603 | |||
| Postoperative NLR (>3.0) | 3.597 | 1.643–7.875 | 0.001 | 15.713 | 1.590–155.227 | 0.018 |
| Postoperative GPS (≥1) | 1.982 | 0.933–4.208 | 0.075 | |||
| Preoperative NLR (>2.5) | 2.204 | 1.023–4.750 | 0.044 | 6.599 | 0.928–46.914 | 0.059 |
| Preoperative GPS (≥1) | 2.723 | 1.372–5.404 | 0.004 | 7.238 | 1.180–44.415 | 0.032 |
CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, NLR neutrophil-to-lymphocyte ratio, CRP C-reactive protein, GPS Glasgow prognostic score
Fig. 4The overall survival subdivided according to the preoperative and postoperative NLR. The patients in group A exhibited a better prognosis compared to the other groups (*p = 0.0124; **p = 0.0202; ***p = 0.0031)